

Curriculum Vitae

Last name, First name: De Jong, Daphne

Gender: female

Nationality/ies: Netherlands

Overall Scientific Expertise:

[Based on your educational and professional backgrounds, please summarise (up to 100 words) your scientific expertise (disciplinary areas, competencies, etc.) especially your health and environmental risk assessment expertise and experience in risk assessment (*if applicable*).]

Since 1986 active as a researcher in malignant lymphoma with a special interest in the application of molecular and immunological knowledge for direct clinical use, both in daily practice and in national and international clinical trials. Principle investigator on various externally funded research programs on molecular characterization of malignant lymphoma, including B-cell lymphomas, T- cell lymphomas and Hodgkin lymphomas. Since 2006 co-leading an epidemiological and biological research program on breast-implant associated anaplastic large cell lymphoma.

Professional Experience

[Starting with your present occupation, list in reverse chronological order each activity in which you have been engaged. Please copy and paste more rows if needed.]

Years employed from – to	Title of position	Employer – name and location	Areas of professional specialisation [▲]
2014-present	Full professor	VU University Medical Center, Amsterdam, the Netherlands	hematopathology
2012-2014	Staff pathologist	VU University Medical Center, Amsterdam, the Netherlands	hematopathology
1993-2012	Sraff pathologist	Netherlands Cancer Institute, Amsterdam, the Netherlands	hematopathology/oncological pathology

[▲][*For example:* toxicology (alternative methods, carcinogenesis, endocrine, immunotoxicity, occupational, exposure assessment, genotoxicity, etc.), chemistry (atmospheric, medicinal, peptide, etc.), physics (biophysics, EMF radiation, noise, etc.), engineering (genetic, environmental, medical, etc.), biology (antimicrobial resistance, biophysics, biotechnology, etc.), medicine (allergies, neurology, etc.), epidemiology (clinical, genetic, cancer, etc.) environmental science (air quality, waste treatment, climate change, ecology, etc.), biostatistics, pharmacokinetics, medical technologies, nanoscience, etc...]

Specific expertise in the field of the call

Since 2006 co-leading a epidemiological and biological research program on breast-implant associated anaplastic large cell lymphoma.

Since 2017 co-founder of the Dutch BIA-ALCL Consortium for multidisciplinary research in BIA-ALCL

As member of the Consortium advisor for governmental organizations on health policy in breast implant related health risk.

Educational Background

[Starting with the most recent, please provide the details of your post-secondary education and/or professional training (e.g. university or its equivalent, postgraduate, postdoctoral). Please copy and paste more rows if needed.]

Year	Degree awarded	Educational Institution – name and location	Areas of educational specialisation*
1986	MD	Leiden University Medical School	
1989	PhD	Leiden University	Malignant lymphoma
1993	Board certification in pathology	Leiden University Medical Center	Hematopathology, oncology

*[For example: chemistry (analytical, organic, etc.), physics (thermodynamics, nuclear, etc.), engineering (mechanical, electrical, chemical, civil, etc.), biology (microbiology, molecular, etc.), medicine (dermatology, oncology, etc.), environmental science, pharmacology, toxicology, etc....]

Memberships in Scientific Advisory Bodies/Committees/Panels (if any):

2000-present: National Pathology database (PALGA), thesaurus working group

2000-present: chair of the regional hematopathology reference board

Regular member of advisory boards for Takeda, Roche, Celgene

Memberships in Learned Societies (if any):

Member of the European Association of Hematopathology (EAHP) (since 1988), secretary-treasurer of EAHP (2008-2016), president of EAHP (2018-2020)

Lunenburg Lymphoma Biomarker Consortium (LLBC), member of the Steering Committee (since 2002), Scientific co-chair (2014-present)

Memberships in Editorial Boards (if any):

2010-2014 Journal of Clinical Oncology Advisory Board

2014-present Associate Editor Histopathology

List of Publications:

[Please indicate the type and total number of your publications. In addition, provide the bibliographic details for the 10 most representative, peer-reviewed articles which highlight the main areas of your scientific expertise.

> 100 publication in peer-reviewed journals, > (co-)author of >15 invited review papers, (co)author for educational book chapters on hematology/hematopathology

1. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. de Boer, M., van Leeuwen, F. E., Hauptmann, M., Overbeek, L. I. H., de Boer, J. P., Hijmering, N. J., Sernee, A., Klazen, C. A. H., Lobbes, M. B. I., van der Hulst, R. R. W. J., Rakhorst, H. A. & **de Jong, D.**, JAMA Oncology. 2018;4, 3, 335-341
2. Miranda RN, Medeiros LJ, Ferrufino-Schmidt MC, Keech JA, Brody GS, **de Jong D** et al. Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. Plastic and reconstructive surgery. 2019 Mar;143(3S):7S-14S.

3. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, **de Jong D**, Doorduijn JK. *Lancet Oncol.* 2019 Feb;20(2):216-228.
4. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Natkunam, Y., Gratzinger, D., Chadburn, A., Goodlad, J. R., Chan, J. K. C., Said, J., Jaffe, E. S. & **de Jong, D.**, 2018, *Blood.* 132, 18; 1871-1878
5. Mendeville M, Roemer MGM, van den Hout MFCM,, **de Jong D**. Aggressive genomic features in otherwise indolent primary HHV8-negative effusion-based lymphoma. *Blood* 2018;
6. Stevens WBC, Mendeville M, Redd R,**de Jong D**. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. *Haematologica.* 2017 Aug;102(8):1413-1423.
7. **de Jong D**, Roemer MG, Chan JK, Goodlad J, Gratzinger D, Chadburn A, Jaffe ES, Said J, Natkunam Y. B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 2. *Am J Clin Pathol.* 2017 Feb 1;147(2):153-170. doi: 10.1093/ajcp/aqw216. As part of a set of 6 co-authored papers covering the 2015 SH/EAHP Workshop Report
8. Chapuy B*, Roemer MGM*, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden E, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon K, Ferry, JA, Freeman G, van Hummelen P, Golub TR, Getz G, Rodig SJ, **de Jong D**, Monti S, Shipp MA: Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. *Blood.* 2016;127:869-81
9. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients Miranda, R. N., Aladily, T. N., Prince, H. M., Kanagal-Shamanna, R., **de Jong, D.**, Fayad, L. E., Amin, M. B., Haideri, N., Bhagat, G., Brooks, G. S., Shifrin, D. A., O'Malley, D. P., Cheah, C. Y., Bacchi, C. E., Gualco, G., Li, S. Y., Keech, J. A., Hochberg, E. P., Carty, M. J., Hanson, S. E. & 15 others, *Journal of Clinical Oncology.* 2014;32, 2, 114-120
10. Salles G, **de Jong D**, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. *Blood.* 2011;117:7070-8.